| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | -0.059 | 0.1 |
| mRNA | BIX02189 | GDSC1000 | pan-cancer | AAC | -0.054 | 0.1 |
| mRNA | PF-573228 | CTRPv2 | pan-cancer | AAC | 0.057 | 0.1 |
| mRNA | Nilotinib | FIMM | pan-cancer | AAC | -0.3 | 0.1 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.073 | 0.1 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.047 | 0.1 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.089 | 0.1 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.053 | 0.1 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | -0.063 | 0.1 |
| mRNA | prochlorperazine | CTRPv2 | pan-cancer | AAC | 0.062 | 0.1 |